

# Potential Phytotherapy use of Artemisia Plants: Insight for Anti-Hypertension

Hmed Ben-Nasr<sup>1</sup>, Mohamed Ali Ben Abderrahim<sup>2</sup>, Mokhtar Salama<sup>1</sup>, Kamilya Ksouda<sup>1</sup>, Khaled-Mounir Zeghal<sup>1</sup>

<sup>1</sup>Laboratory of Pharmacology, Medicine Faculty of Sfax; Rue Magida Boulila 3029, Sfax- Tunisia.

<sup>2</sup>Institute of Arid Regions, Chenini; Gabes – Tunisia.

---

## ARTICLE INFO

### Article history:

Received on: 11/01/2013

Revised on: 22/02/2013

Accepted on: 15/03/2013

Available online: 30/05/2013

### Key words:

Artemisia – blood pressure –  
cardiovascular – therapy.

---

---

## ABSTRACT

Artemisia plants had been used to treat many diseases. While there many controversies concerning their effects on the cardiovascular system, Artemisia extracts could be envisaged as anti-hypertensive and to prevent cardiovascular damages. In reason of its bare toxicity, using the crude extracts will be of much importance in this field.

## INTRODUCTION

Hypertension is a trait of multifactorial nature with both genetic and environmental influences; and usually associates with other diseases and pathological complications. Although the outstanding advances in medicine and related technologies and sciences, hypertension is still a worldwide major problem with a projected occurrence of 1,56 billion patients, in 2025 (Kim *et al.*, 2010).

Many cardiovascular conventional drugs, even as efficient, did present adverse outside effects; and so much safe therapeutic substances are in need. The therapeutic approaches become more and more ambiguous, when the disorder is associated with other pathological conditions such as diabetes mellitus and obesity. Else more, there are several mechanisms leading to hypertension.

Mending one of them, whenever ameliorates the case, did not totally relief the illness (refce?1,2??). Recently, evidenced knowledge proved the utility and safety of various medicinal plants against many pathologic disorders (Mohanty *et al.*, 2012). Artemisia, plants from the Asteraceae, had been used from the

olden days against many diseases. Its therapeutic usefulness gained much popular and scientific approval; but this plant effects on the cardiovascular system remain unclear. So, this paper put forward new insight for the utilization of Artemisia plants to counteract cardiovascular diseases with special focus on hypertension.

## Artemisia description

*Artemisia* genus (Asteraceae, Anthemideae, Artmisiinae) comprises hundreds (about 500) of different species, but its systematic classification remains discussed. In general five different subtaxa are considered (Torrell and Valles, 2001; Valles and McArthur, 2001).

This complexity arose from its genomic 'polymorphism', essentially the ploidy levels sought as the promoter mechanism for evolution and ecological adaptation (Badr *et al.*, 2012; Torrell and Valles, 2001). Artemisia shrub occupies worldwide geographical areas; and attracted much attention for its highly economic values, in particular for its medicinal patterns. Rationally these plants were used from the olden days as, anti-venom, anthelmintic, antidepressant, antiseptic, diuretic, antispasmodic, hypoglycemic, anti-cancer etc., throughout the World; and were subjected to intensive scrutiny (Ashraf *et al.*, 2010a,b; Gautam *et al.*, 2003; Lai, 2009; Tardio *et al.*, 2006).

---

\* Corresponding Author

Hmed Ben-Nasr.

Address: Laboratory of Pharmacology, Medicine Faculty of Sfax; Rue Magida Boulila 3029, Sfax- Tunisia.

Phone: (216) 74 247 036; Fax: (216) 74 246 217.

Amongst these customary phytotherapeutic uses, the artemisinin which is isolated from the Chinese *Artemisia annua* L showed important anti-malarial effects and owed great attention for treating such disease particularly in less developed countries (Wilcox *et al.*, 2004; De Ridder *et al.*, 2008; Muzemil, 2008; Tu, 2011; Ho, 1996; Germer and Sinar, 2010). As well, many other compounds have been characterized in this vegetal that act through disparate pathways in diseases' curing.

Additionally, *Artemisia* extracts showed no real toxicological patterns, an indispensable feature for pharmaceutical use (Mukina, 2005; Mansi and Lahham, 2008). Besides its genetic and ecological diversity, inter and intra-specific variability in *Artemisia* chemical composition was proved, and might explain the diversity of extracts' biological activities and ethno-pharmacy. Obviously, *Artemisia* extracts potently scavenge free radical compounds (Canadanovic-Brunet *et al.*, 2005; Wang *et al.*, 2007; Ayoughi *et al.*, 2011; Wojcikowski *et al.*, 2007) that are common traits of many diseases (Higdon *et al.*, 2012; Dalle-Donne *et al.*, 2006). However, there were controversial findings concerning *Artemisia* extracts on cardiovascular system regulation.

#### Chemical composition of *Artemisia* shrub

*Artemisia* shrub is a rich source of bioactive substances such as apigenin, hesperetin, kaempferol, luteolin, quercetin, 1,8-cineole; alpha- and beta- thujone, camphor, borneol) coumarin, acetylenes; and many other substances (table 1).

Nonetheless, important qualitative and quantitative variability in the chemical composition of the plant extracts, exist not only between different species, but also intra-specifically within the geographical localization and the ecological milieu (soil and climate) (Judzentiene and Buzelyte, 2006; Salido *et al.*, 2004). For example, the total phenolic acids produced by in vitro cultured cells and extracted using 70% methanol, greatly differ between *A. frigida*, *A. campestris* and *A. vulgaris* plants (173,9, 75,2 and 69,5  $\mu\text{mol/g}$  of dry weight; respectively) (Riedel *et al.*, 2010). Further chemical changes could also be observed dependently on the biological cycle (Germination, Flowering, seedling and Fructification); and the used part of the vegetal (Judzentiene and Buzelyte, 2006).

Methods of extraction (aqueous, ethanol, etc.) and/or traditional application (drinking, ointment, inhalation, etc.) add much persuasive miscellany to its therapeutic potential (Salido *et al.*, 2004; Vinatoru *et al.*, 1997; Naczka and Shahidi, 2004). In addition, *Artemisia* organs are exceptionally enriched in Chloride,  $\text{HCO}_3$ ,  $\text{SO}_4$ , fluoride, sodium, potassium, magnesium and many other minerals (Hussain *et al.*, 2011; Ashraf *et al.*, 2010). We will discuss some of these tremendously influencing factors, reliably to the sought cardiovascular effects of the plant.

#### Anti-hypertensive effects of *Artemisia* extracts

Using animal model, Esmaeili *et al.* (2009) proved that *A. Persia* extracts reversed the epinephrine induced- hypertension much more than enalapril, a conventional anti-hypertensive drug. However, the real mechanisms of these effects are still blurred

(table 2). Such divergence could be attributed to the quantitative and qualitative chemical composition variability, as discussed above. In fact, many *Artemisia* derivatives might modulate the heart and vascular function either directly or indirectly through the control of endocrine and, or nervous cardiovascular regulations.

#### Neuronal modulation

Pharmacologically, the dosage and routes of administration are prominent influencing factors. The application of moxa, which is the inhalation of volatilized substances during the plant burning, may firstly affect the pulmonary tissues (Novak *et al.*, 1993) and consequently exert pulmonary vasodilatation that probably help into pulmonary diseases healing such as asthma and bronchospasm (Chen

g *et al.*, 2011). Interestingly, in this Chinese therapy, general body depression and heart rate decrease are common occurrences (Kim *et al.*, 2010; Zhao *et al.*, 2011). Many investigations brought substantial knowledge on such process. In sub-chronically or acutely exposed animals to *Artemisia* derivatives, a decrease in heart rate and systolic blood pressure was observed in association to aorta and heart lowered responsiveness to the contractile epinephrine and enhanced response to acetylcholine (Tigno *et al.*, 2000; Esmaeili *et al.*, 2009 and 2012; Mojarad *et al.*, 2005).

The vascular smooth muscle relaxation was similarly induced in rabbit jejunum following *A. herba-alba* essential oils application (Aziz *et al.*, 2012). To understand the mechanism of this relaxation, five flavonoids (jaceosidine, eupafolin, leuteolin, quercetin and apigenin) and three coumarins (aesculetin, aesculetin 7- methyl ether and scopoletin) have been extracted from the Korean mugwort (*A. vulgaris* L.) and assayed to determine their inhibitory capacities on the brain monoamine oxidase. This enzyme plays a key role in various neuromediators metabolism such as, epinephrine, nor-epinephrine, dopamine and serotonin (Lee *et al.*, 2000).

The isolated *Artemisia* chemicals abolished this enzyme activity with  $\text{IC}_{50}$  ranging from 1 to 45  $\mu\text{mol}$ . This might result in epinephrine production fail, and thereby counteract hypertension (Lee *et al.*, 2000). Consequently, it is suggested that *Artemisia* compounds modulates the cardiovascular function at the neuro-vascular (expectedly neuro-cardiac, too) bed through the regulation of neurotransmitters and their appropriate receptors interactions. Accordingly, smelling essential oils of *A. dracuncululus* and *A. vulgaris* stimulates the sympathetic activity that changes the low frequency amplitude of blood pressure, perhaps via adrenaline concentration shift (Haze *et al.*, 2002, Zhao *et al.*, 2011).

In an elegant fashion, Luedtke and collaborators (2003) examined the competitive potential of various plants derivatives binding to D1 and D2 dopaminergic receptors in modified Human cells; Amongst these studied compounds, the *A. anomala* (estragon) unspecifically binds to both receptors with a preference to D1 (D1:D2= 2). Interestingly, the extract inhibited the adenylyl cyclase activity that mediated the signal transmission; but independently from binding to receptors (Luedtke *et al.*, 2003).

In summary, the nervous mediated regulation of the cardiovascular function by *Artemisia* shrub extracts appears to be mediated by functional inhibition of enzymes controlling neurotransmitters release.

The competitive binding to adrenergic receptors is thought to be ineffective docking- interactivity, or following the compound interaction with an appropriate site in close proximity to adrenergic receptors that will interact with the compound in allosteric manner, like as how did hispidulin, a flavone found in many *Artemisia* species (Kavvadias *et al.*, 2004). The direct (independent from receptor stimulation/ inhibition) abolishing of adenyl cyclase and its mediated signal, constitutes another possible hypotensive mechanism for *Artemisia* extracts.

### Endocrine regulation

Nitric oxide (NO) is prominent endogenous vasodilator acting through the activation of the soluble guanylyl cyclase, and increases the cyclic guanosine-3':5'-monophosphate (cGMP) in smooth muscles (Bigaud *et al.*, 1990). Whilst required at low concentration to maintain hemodynamic equilibrium, the NO excessive release contributes to circulatory shock and cell death through its potential to react with oxygen species (ROS). The ROS property of NO is engulfed into the endorsed oxidant/anti-oxidant system (Achike and Kwan, 2003).

In studies using knockout mice deficient to endothelial nitric oxide synthase (eNOS) and cyclooxygenases-1 (COX-1), Scotland and colleagues proved that NO, PGI<sub>2</sub> (prostaglandin I<sub>2</sub>) and EDHF (endothelium-derived hyperpolarizing factor) acts synergistically in retrieving blood pressure increase.

They concluded for a gender dependant-divergence on this process: (i) the eNOS and COX-1 deficiency profoundly breakdown the NO and PGI<sub>2</sub> hypotensive effect in males; (ii) in contrary, the EDHF pathway dominates the process in females (Scotland *et al.*, 2005). In accordance, Ryu and colleagues (1998) mentioned that yomogin (*A. verlotorum lamottei*) potently inhibited the inducible form of NOS, and thereby will abolish the vasodilator NO production, as like as did extracts from *A. abstinium* (quercetin) (Mahmoudi *et al.*, 2009) and *A. herba alba* (Messaoudene *et al.*, 2011). Irrespectively, *Artemisia* extracts mostly induced a blood pressure decrease, and it is attended to get NO overproduction at the time of treatment (Yamahara *et al.*, 1989a, b; Calderone *et al.*, 1999). Since the iNOS inhibition was localized into blood cells (Ryu *et al.*, 1998), it is supposed to marginally affect the vessels tonus. Consequently, the observed NO increase will probably originate from eNOS activity or released from adjacent nervous terminations. Instead of inducing NO production, *Artemisia* extracts appeared to stimulate the cGMP-dependent signaling pathway of the nitric oxide which contributes to smooth muscles relaxation.

Furthermore, other mediators, such as histamine and substance P, could mandate this induced hypotension (Okazaki *et al.*, 1990).

### Blood rheology and cardiovascular protection

Many researches showed that *Artemisia* compounds improve the blood rheology, essentially through their anti-thrombosis activity which prevents blood clot formation, reduces the sheer stress and enhances blood circulation, especially in microvasculature (Harborne *et al.*, 2000; Shahriyary and Yazdanparast, 2009). The modus operandi of anti-thrombosis might involve the peroxisome proliferator-activated receptors (PPARs) components st

imulation (O'Brien *et al.*, 2006). So, the increased mRNA expression of PPARs by *A. iwayomogi*, in combination to *Morruus alba* and *Melissa officinalis* is envisaged to recover platelet aggregation and thrombosis (Lee *et al.*, ???), Furthermore, cardiovascular dysfunction and tissular damages are roughly subsequent to ROS generation (Dalle-Donne *et al.*, 2006). Reestablishing the oxidant / anti- oxidant system equilibrium constitutes a basic mechanism for cardiovascular diseases therapy. Thus, it is fair-minded to apply *Artemisia* treatments to prevent these disorders, because of its powerful ROS scavenging potential (Akrouit *et al.*, 2012; Wojcikowski *et al.*, 2007, Wang *et al.*, 2007; Ayoughi *et al.*, 2011; Canadanovic-Brunet *et al.*, 2005, Kadri *et al.*, 2011).

Infective endocarditis is a pathogenic disease. It is characterized by lesions consisting of vegetations including platelets, fibrin, microorganisms and inflammatory cells; in association to vessel bed disruption (Thiene and Basso, 2006). For that reason, *Artemisia* extracts could be envisaged as therapeutic for infective endocarditis; not only for its antimicrobial potential (Khanahmadi *et al.*, 2009), but for the above mentioned patterns (anti-thrombotic, anti-oxidant) and its anti-inflammatory effects (Messaoudene *et al.*, 2011), too. The cardiovascular dysfunction is, also, a frequent occurrence in lipids and glucose metabolic disorders. By lowering serum triglycerides, cholesterol and glucose concentrations; and reestablishing insulin function (Watcho *et al.*, 2010 and 2011; Weinohrl, 2010), *Artemisia* holding substances may recover the vascular resistance and blood circulation.

Else more, given that the cardiovascular and urinary functions are tightly dependent one on the other, attenuating kidneys dysfunction is thought to ameliorate the blood circulation. In this view of point, the combined use of cordyceps (fungi) powder and artemisinin (2-4:0,6 w/w) efficiently protects the kidney function into patients with lupus nephritis unresponsive to corticosterone and cyclophosphamide (reviewed by Wojcikowski *et al.*, 2004).

The 20- hydroxeicosatetraenoic acid inhibition by the sesame (a lignan isolated from *Artemisia*) will improve sodium reabsorption in the renal proximal tubule and consequently modulates natriuresis pressure (Miyata and Roman, 2005; Wu *et al.* 2009). Eventually, the richness of *Artemisia* plant in various minerals (Hussain *et al.*, 2011; Ashraf *et al.*, 2010) will improve the blood rheology and homeostasis.

**Table 1:** list of the first 10<sup>th</sup> dominant compounds characterized in hydro-distilled essential oils of various *Artemisia* species.

<i>A. hahsknechtii</i>		<i>A. abrotanum</i>		<i>A. dracunculus</i>		<i>A. herba-alba</i>	
Camphor	12,4	Piperitone	17,5	(Z)-Anethole	51,7	$\beta$ -Thujone	68,4
$\alpha$ -Tepineol	9,9	Dawanone	16,7	Elemicin	48,7	Camphor	68,2
Davanana ether	6,2	1,8 Cineole	12,5	Sabinene	18,8	$\alpha$ -Thujone	57
Borneol	4,9	Artedouglasia oxide B	6,7	(E)-Asarone	13,3	Davanone	51,2
Ipsdienol	4,5	Silphiperfol-5-en-3-ol A	6,2	(Z)- $\beta$ - Ocimene	8,3	Chrysanthene	36,4
Borneol acetate	3,7	Germacrene D	5,8	Methyl-eugenol	8,0	Cis-Chrysanthenol	27,8
1,8 Cineole	3,7	Artedouglasia oxide D	4,7	Limonene	4,9	1,8 Cineole	25,8
Yomogi alcohol	3,5	Siphiperfol-5-en-3-one A	2,5	Linalool	4,4	p-Cymene	20,6
p_Cimene	3,2	Ocymene	2,3	$\alpha$ -Terpinene	3,8	Cis-Chrysantenyl acetate	18,4
Neryl acetate	3,2	Artedouglasia oxide C	1,8	Allo-Ocimene	3,2	$\alpha$ -Pinene	17,2


  

<i>A. vulgaris</i>		<i>A. sieberi</i>		<i>A. khorasanica</i>	
Camphor	47,7	$\beta$ -Thujone	19,8	Davanone	36,4
Isobronyl isobutyrate	38,0	Camphor	19,5	p-Cymene	16,5
Caryophyllene oxide	31,1	$\alpha$ -Thujone	10,6	(Z)-Citral	8
$\beta$ -Pinene	30,1	Verbenol	9,7	$\beta$ - Ascaridol	5,9
$\beta$ -Thujone	20,8	p-mentha-1,5-dien-8-ol	6,4	(Z)- Jasmone	3,8
$\alpha$ -Phellandrene	17,3	Davanone	5,8	Thymol	3,7
Luratol	15,1	1,8- Cineol	5,7	Linalool	2,5
Trans- isoelemicin	15,1	Camphene	3,6	1,8-Cineol	2
$\alpha$ -Pinene	15	$\alpha$ -Pinene	2,5	Zingiberene	1,8
1,8 -Cineol	11,7	p- Cymene	1,2	$\alpha$ -Pinene	1,7

Values represent the maximal abundance (%) of compounds, as quantified using Gas-Chromatography, checked across the reported literature: Ayoughi, *et al.*, 2011; BenJilali and Richad, 1980; Ghorbani-Ghouzdi *et al.*, 2008; Judzentiene *et al.*, 2006; KhanAhmadi *et al.*, 2009; Kowaliski *et al.*, 2007 and 2011; Tajadod *et al.*, 2012; and Salido *et al.*, 2004.

**Table 2:** divergent effects of some *Artemisia* extracts or derivatives on the cardiovascular function.

Plant	Extract / compound	Effect	Refce
<i>A. capillaris</i> (flos)	Scoparone	Increase heart rate and coronary flow. No influence on cardiac output and LV performance Inhibition of the ST wave (antianginal action)	Yamahara <i>et al.</i> , 1989a, b
<i>A. annua</i>	Artesunate (derived artemisinin)	Inhibit angiogenesis	Dell'Eva <i>et al.</i> , 2004
<i>A. verlotorum</i>	Water extract	Transient hypotension in mesentery	Calderone <i>et al.</i> , 1999
<i>A. vulgaris</i>		No effect on heart and mean arterial pressure Hypotension in mesenteric arteries	Tigno <i>et al.</i> , 2000
<i>A. persia</i>	Methanol and water	Reduces heart rate and systolic blood pressure	Esmaili <i>et al.</i> , 2012
<i>A. vulgaris</i>	Moxa	Reduces heart rate	Zhao <i>et al.</i> , 2011
<i>A. annua</i>		enhances the acetylcholine induced endothelial-dependent relaxation of aorta	Mojarad <i>et al.</i> , 2005



**Fig.1:** overall schematic representation for the anti-hypertensive effect of *Artemisia* extracts. The circled sequences stand for experimentally or clinically evidenced actions of *Artemisia* extracts. Abbreviations: GMP: guanosidine monophosphate, MAO: monamine oxidase, NO: nitric oxide, PGI2: prostaglandin I2; and ROS: reactive oxygen species.

### Concluding remarks

Much scientific researches pointed toward the anti-hypertensive utility of *Artemisia* plants. However, there was no succinct experimental or clinical works delineating its real mechanisms and the involved contained compounds. Nevertheless, using whole extracts of *Artemisia* could better improve the cardiovascular disorder, since they combined many biological activities that are effective in concurrently healing many disorders (Figure 1). Likely, the effects of these plants extracts on blood pressure are thought to originate, essentially, from the inhibitions of the adenylyl cyclase and stimulation of cGMP enzymes. In such manner, there will be dampened energetic machinery which is needed for vascular constriction. Perspective systemic works are required to outline the importance of whole *Artemisia* extracts against cardiovascular disorders. A pharmacological model putting into a head objective the anti-hypertensive and cardiovascular protector effects of *Artemisia* extracts will inevitably improve our understanding of such effects and delineate the utility of these plants in this field.

### REFERENCES

- Achike F.I., Kwan C-Y. nitric oxide, human diseases and the herbal products that affect the nitric oxide signaling pathway. *Clin. Exp. Pharmacol. Physiol.* 2003; 30: 605-615.
- Akrout A., Mighri H., Krid M., Thabet F., Turki H., El-Jani H., Neffati M. chemical composition and antioxidant activity of aqueous extracts of some wild medicinal plants in southern Tunisia. *Int. J. Life Sci. Med. Sci. LSMR.* 2012; 2: 1-4.
- Ashraf M., Hayat M.Q., Jabeen S., Shaheen N., Ajab M., Yasmin G. *Artemisia L.* species recognized by the local community of northern areas of Pakistan as folk therapeutic plants. *J. Med. Plants Res.* 2010; 4: 112-119.
- Ashraf M., Hayat M.Q., Mumtaz A.S. a study on elemental contents of medicinally important species of *Artemisia L.* (Asteraceae) found in Pakistan. *J. Med. Plants Res.* 2010; 4: 2256-2263.
- Ayoughi F., Barzegar M., Sahari M.A., Naghdibadi H. chemical compositions of essential oils of *Artemisia dracuncululus L.* and endemic *Matricaria chamomilla L.* and an evaluation of their anti-oxidative effects. *J. Agr. Sci. Tech.* 2011; 13: 79-88.
- Aziz M., Karim A., El-Ouariachi E-M., Bouyanzer A., Amrani S., Mekhfi H., Ziyat A., Melhaoui A., Bnouham M., Legssyer A. relaxant effects of essential oil of *Artemisia herba-alba* asso. On rodent jejunum contractions. *Sci. Pharm.* 2012; 80: 457-467.
- Badr A., Morsy W., Abdelfattah S., Shams S., Shehab A. genetic diversity in *Artemisia monosperma* and *Artemisia judaica* populations in Egypt based on morphological, karyological and molecular variations. *J. Med. Plants Res.* 2012; 6: 66-78.
- BenJilali B., Richard H. etude de quelques peuplements d'Armoise blanche du Maroc *Artemisa herba alba*. *Rivista Italiana, E.P.P.O.S.*, 1980 ; LXII ; pp 69-74.
- Bigaud M., Julou-Schaffer G., Parrant J.R., Stoclet J.C. endotoxin- induced impairment of vascular smooth muscle contractions elicited by different mechanisms. *Eur. J. Pharmacol.* 1990; 190: 185-192.
- Calderone V., Martinotti E., Baragatti B., Breschi M.C., Morelli I. vascular effects of aqueous crude extracts of *Artemisia verlotorum lamootte* (Compositae): in vivo and in vitro pharmacological studies in rat. *Phytother. Res.* 1999; 13: 645-648.
- Canadanovic-Brunet J.M., Djilas S.M., Cetkovic G.S., Tumbas V.T. free-radical scavenging activity of wormwood (*Artemisia absinthium L.*) extracts. *J. Sci. Food Agric.* 2005; 85: 265-272.
- Cheng C., Ho W.E., Goh F.Y., Guan S.P., Kong L.R., Lai W-Q., Leung B.P., Wong W.S.F. anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. *PLoS ONE.* 2011 ; -(6) : e20932. Doi :10.1371/journal.pone.0020932.
- Dalle-Donne I., Rossi R., Colombo R., Giustarini D., Milzani A. biomarkers of oxidative damage in Human disease. *Clin. Chem.* 2006; 52: 601-623.
- De Ridder S., van der Kooy F., Verpoorte R. *Artemisia* as a self-reliant treatment for malaria in developing countries. *J. Ethnopharmacol.* 2008; 120: 302-314.
- Dell'Vera R., Pfeffer U., Vene R., Anfosso L., Forlani A., Albini A., Efferth T. inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. *Biochem. Pharmacol.* 2004; 68: 2359-2366.
- Esmaeli F., Sepehri G., Moshtaghi-Kashanian G-R., Khaksari M., Salari N., Sepehri E. the effect of acute administration of *Artemisia Persia* extracts on arterial blood pressure and heart rate in rats. *Am. J. Appl. Sci.* 2009; 6: 843-847.
- Esmaeli F., Sepehri G., Joneidi H., Daneshvar S., Hasannejad M. cardiac effects of subacute administration of *Artemisia Persia* extract in normotensive and hypertensive rats. *Ann. Biol. Res.* 2012; 3: 34043-3409.
- Gautam K., Imakawa C., Watanabe T. (2003). multiple uses of *Artemisia* species in Japan and Nepal. Himalyan Document Centre. WWW.Lib.icimod.org.
- Germier J., Sinar E. pharmaceutical consumption and residuals potentially relevant to nutrient cycling in greater Accra, Ghana. *J. Agr. Rural Develop. Trop. Subtrop.* 2010; 111: 41-53.
- Ghorabni-Ghouzdi H., Sahraro A., Asghari H.R., Abdasdokht H. compositor of essential oils of *Artemisia sieberi* and *Artemisia khorasanica* from Iran. *World Appl. Sci. J.* 2008; 5: 363-366.
- Harborne J.B., Williams C.A. advances in flavonoid research since 1992. *J. Phytochem.* 2000; 55: 481-504.
- Haze S., Sakai K., Gozu Y. effects of Fragrance inhalation on sympathetic activity in normal adults. *Jpn. J. Pharmacol.* 2002; 90: 247-253.
- Higdon A., Diers A.R., Oh J.Y., Landar A., Darley-USmar V.M. cell signaling by reactive lipid species: new concepts and molecular mechanisms. *Biochem. J.* 2012; 442: 453-464.
- Ho NK. Traditional chinese medicine and treatment of neonatal jaundice. *Singapore Med. J.* 1996; 37: 645-651.
- Hussain I., Khan F.A., Khattak M.U.R., evaluation of inorganic profile of selected medicinal plants of Kyber Pakhtunkhwa Pakistan. *World Appl. Sci. J.* 2011; 12: 1464-1468.
- Judzentiene A., Buzelyte J. chemical composition of essential oils of *Artemisia vulgaris L.* (mugwort) from North Lithuania. *CHEMIJA*, 2006; 17: 12-15.
- Kadri A., Ben Chobba I., Zarai Z., Bekir A., Gharsallah N., Damak M., Gdoura R. chemical constituents and antioxidant activity of the essential oil from aerial parts of *Artemisia herba-alba* grown in Tunisian semi-arid region. *Afr. J. Biotechnol.* 2011; 10: 2923-2929.
- Kavvadias D., Sand P., Youdim K.A., Qaiser M.Z., Rice-Evans C., Baur R., Sigel E., Rausch W-D., Riederer P., Schreier P. the flavones hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. *Br. J. Pharmacol.* 2004; 142: 811-820.
- Khanahmadi M., Rezazadeh Sh., Shahrezei F., Taran M. study on chemical composition of essential oil and anti-oxidant and anti-microbial properties of *Artemisia haussknechtii*. *J. Med. Plants*, 2009; 8: 132-141.
- Kim J-I, Choi J-Y., Lee H., Lee MS., Ernst E. moxibustion for hypertension: a systemic review. *BMC Cardiovascul. Disorders.* 2010, 10:33.
- Kowalski R., Wawrzykowski J., Zawislak G. analysis of essential oils and extracts from *Artemisia abrotanum L.* and *Artemisia dracuncululus L.* *Herba Polonia.* 2007; 53: 246-254.
- Lai G. isolation of a compound from *Artemisia douglasiana* that is cytotoxic toward breast cancer cells. Thesis Dissertation, University of California, USA; 2009. Lee J., Chae K., Ha J., Park B-Y., Lee HS., Jeong S., Km M-Y., Yoon M. regulation of obesity and lipid disorders by herbal extracts from *Morus alba*, *Melissa officinalis*, and *Artemisia capillaris* in high-fat diet - induced obese mice. *J. Ethnopharmacol.* 2008; 115: 263-270.

- Lee S-J., Chung H-Y., Lee I-K., Oh S-U., Yoo I-D. phenolics with inhibitory activity on mouse brain monoamine oxidase (MAO) from whole parts of *Artemisia vulgaris* L (Mugwort). *Food Sci. Biotechnol.* 2000; 9: 179-182.
- Luedtke R.R., Freeman R.A., Volk M., Arfan M., Reinecke M.G. pharmacological survey of medicinal plants for activity at dopamine receptor subtypes .II. screen for binding activity at the D1 and D2 dopamine receptor subtypes. *Pharmaceut. Biol.* 2003; 41: 45-58. (artem extract dopaminergic effects)
- Mahmoudi M., Ebrahimzadeh M.A., Ansaroudi F., Nabavi S.F., Nabavi S.M. antidepressant and antioxidant activities of *Artemisia absinthium* L. at flowering stage. *Afr. J. Biotechnol.* 2009; 8: 7170-7175.
- Mansi K., Lahham J. effects of *Artemisia sieberi* besser (A. herba-alba) on heart rate and some hematological values in normal and alloxan-induced diabetic rats. *J. Basic Appl. Sci.* 2008; 4: 57-62.
- Messaoudene D., Belguendouz H., Ahmedi M-L., Benabdelkader T., Otmani F., Terahi M., Youinou P., Touil-boukoffa C. ex vivo effects of flavonoids extracted from *Artemisia herba alba* on cytokines and nitric oxide production in Algerian patients with adamantiades-behçet's disease. *J. Inflamm.*, 2011; 8:35.
- Miyata N., Roman R.J. role of the 20- hydroxyeicosatetraenoic acid (20-HETE) in vascular system. *J. Smooth Muscle Res.* 2005; 41: 175-193.
- Mohanty I.R., Gupta S.K., Mohanty N., Joseph D., Deshmukh Y. the beneficial effects of herbs in cardiovascular diseases. *Global J. Med. Res.* 2012; 12: 38- 58.
- Mojarad T.B., Roghani M., Zare N. effect of subchronic administration of aqueous *Artemisia annua* extract on  $\alpha 1$ - adrenoceptor agonist-induced contraction of isolated aorta in rat. *Iran. Biochem. J.* 2005; 9: 57-62.
- Mukinda J.T. acute and chronic toxicity of the flavonoid-containing plant, *Artemisia afra* in rodents. Thesis Dissertation, University of the Western Cape, School of Pharmacy, South Africa; 2005.
- Muzemil A. determination of artemisinin and essential oil contents of *Artemisia annua* L. grown in Ethiopia and in vivo antimalarial activity of its crude extracts against *Plasmodium berghei* in mice. Thesis Dissertation, University of Addis Ababa; School of Pharmacy- Ethiopia 2008.
- Nacz M., Shahidi F. extraction and analysis of phenolics in food. *J. Chromatography A.* 2004; 1045: 95-111.
- Novac V., Novak P., Champlain J.D., Blanc A.R.L., Martin R., Nadeau R. influence of respiration on heart rate and blood pressure fluctuations. *J. Appl. Physiol.* 1993; 74: 617-626.
- O'Brien J.J., Ray D.M., Spinelli S.L., Blumberg N., Taubman M.B., Francis C.W., Wittlin S.D., Phipps R.P. the platelet as a therapeutic target for treating vascular diseases and the role of eicosanoids and synthetic PPAR $\gamma$  ligands. *Prostaglandins & other Lipid Mediators*, 2007; 82: 68-76.
- Okazaki M., Aizawa S., Yamauchi M., Oguchi K. effects of single moxibustion on cutaneous blood vessel and microvascular permeability in mice. *Am. J. Chin. Med.*, 1990; 18: 121-130.
- Riedel H., Cai Z., Kutuk O., Smetanska I. obtaining phenolic acids from cell cultures of various *Artemisia* species. *Afr. J. Biotechnol.* 2010; 9: 8805-8809. Ryu J.H., Lee H.J., Jeong Y.S., Ryu S.Y., Han Y.N. yomogin, an inhibitor of nitric oxide production in LPS-activated macrophages. *Arch. Pharm. Res.* 1998; 21: 481-484.
- Salido S., Valenzuela L.R., Altarejos J., Noguera M., Sanchez A., Cano E. composition and intraspecific variability of *Artemisia herba-alba* from southern Spain. *Biochem. Sys. Ecol.* 2004; 32: 265-277.
- Scotland R.S., Madhani M., Chauhan S., Moncada S., Andresen J., Nilsson H., Hobbs A.J., Ahluwalia A. investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenases-1 double-knockout mice; key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. *Circulation.* 2005; 111: 796-803.
- Shahriyari L., Yazdanparast . antiplatelet and antithrombotic activities of *Artemisia dracunculoides* L. leaves extract. *Pharmacologyonline.* 2009; 1: 217-228.
- Tajadod G., Mazooji A., Salimpour F., Samadi N., Taheri P. the essential oil composition of *Artemisia vulgaris* L. in Iran. *Ann. Biol. Res.* 2012; 3: 385-389.
- Tardio J., Pardo-de-Santayana M., Morales R. ethnobotanical review of wild edible plants in Spain. *Botan. J. Linn. Soc.* 2006; 152: 27-71.
- Thiene G., Basso C. pathology and pathogenesis of infective endocarditis in native heart valves. *Cardiovasc. Pathol.* 2006; 15: 256-263.
- Tigno X.T., de Guzman F., Flora A.M. phytochemical analysis and hemodynamic actions of *Artemisia vulgaris* L. *Clin. Hemorheol. Microcirc.* 2000; 23: 167-175.
- Torrell M., Valles J. genome size in 21 *Artemisia* L. species (Asteraceae, Anthemideae): systemic, evolutionary, and ecological implications. *Genome* 2001; 44: 231-238.
- Tu Y. the discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nature Med.* 2011; 17: 19-22.
- Valles J., McArthur E.D. *Artemisia* systematic and phylogeny: cytogenetic and molecular insights. *USDA Forest Service Proceedings RMRS-P621.* 2001; pp: 67-74.
- Vinatoru M., Toma M., Radu O., Filip P.I., Lazurca D., Mason T.J. the use of ultrasound for the extraction of bioactive principles from plant materials. *Ultrason. Sonochem.*, 1997; 4: 135-139.
- Wang Y., Yin J., Qiao Y., Zhang H., Lu X. studies on antioxidant activity and chemical constituents of *Artemisia halodendron*. *Asian J. Trad. Med.* 2007; 2: 30-33.
- Watches P., Stavniichuk R., Ribnický D.M., Raskin I., Obrosova I.G. high-fat diet- induced neuropathy of prediabetes and obesity: effect of PMI-5011, an ethanolic extract of *Artemisia dracunculoides* L. *Mediators Inflamm.* 2010. Doi:10.1155/2010/268547.
- Watches P., Stavniichuk R., Tane P., Shevalye H., Maksimchyk Y., Pacher P., Obrosova I.G. evaluation of PMI-5011, an ethanolic extract of *Artemisia dracunculoides* L., on peripheral neuropathy in streptozotocin-diabetic mice. *Int. J. Mol. Med.* 2011; 27: 299-307.
- Weinohrl S.E. screening of various extracts of *Artemisia dracunculoides* L. for antidiabetic activity in rats. Master of Pharmacy, Dissertation of Universität Wien- German; 2010.
- Wilcox M., Boderker G., Bourdy G., Dhingra V., Falquet J., Ferreira J.F.S., Graz B., Hirt H-M., Hsu E., de Magalhães P.M., Provendier D., Wright C.W. *Artemisia annua* as a traditional herbal antimalarial. *CRC Press LLC.*, 2004.
- Wojcikowski K., Johnson D.W., Gobe G. medicinal herbal extracts- renal friend or foe? Part two: herbal extracts with potential renal benefits. *Nephrology* 2004; 9: 400-405.
- Wojcikowski K., Stevenson L.M., Leah D.N., Wohlmuth H., Gobe G. antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using sequential three solvent extraction process. *J. Altern. Compl. Med.* 2007; 13: 103-109.
- Wu JHY., Hodgson JM., Clarke M.W., Indrawan AP., Barden AE., Puddey IB., Croft KD. Inhibition of 20-hydroxyeicosatetraenoic acid synthesis using specific plant lignans: in vitro and Human studies. *Hypertension.* 2009; 54: 1151-1158.
- Yamahara J., Kobayashi G., Matsuda H., Katayama T., Fujimura H. the effect of scoparone, a coumarin derivative isolated from the Chinese crude drug *Artemisia capillaris* flos, on the heart. *Chem. Pharmacol. Bull.* 1989; 37: 1297-1299.
- Yamahara J.K.G. vascular dilatory action of *Artemisia capillaris* bud extracts and their active constituent. *J. Ethnopharmacol.* 1989; 26: 129-136.
- Zhao B., Litscher G., Li J., Wang L., Cui Y., Huang C., Liu P. effects of Moxa (*Artemisia vulgaris*) smoke inhalation on heart rate and its variability. *Chinese Med.* 2011; 2: 53-57.

#### How to cite this article:

Hmed Ben-Nasr, Mohamed Ali Ben Abderrahim, Mokhtar Salama, Kamilya Ksouda, Khaled-Mounir Zeghal., Potential Phytotherapy use of *Artemisia* Plants: Insight for Anti-Hypertension. *J App Pharm Sci*, 2013; 3 (05): 120-125.